[go: up one dir, main page]

FR11C0002I2 - POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT - Google Patents

POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT

Info

Publication number
FR11C0002I2
FR11C0002I2 FR11C0002C FR11C0002C FR11C0002I2 FR 11C0002 I2 FR11C0002 I2 FR 11C0002I2 FR 11C0002 C FR11C0002 C FR 11C0002C FR 11C0002 C FR11C0002 C FR 11C0002C FR 11C0002 I2 FR11C0002 I2 FR 11C0002I2
Authority
FR
France
Prior art keywords
pct
person
narrowing
asthma
susceptibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0002C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sydney West Area Health Service SWAHS
Original Assignee
Sydney West Area Health Service SWAHS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sydney West Area Health Service SWAHS filed Critical Sydney West Area Health Service SWAHS
Publication of FR11C0002I1 publication Critical patent/FR11C0002I1/fr
Application granted granted Critical
Publication of FR11C0002I2 publication Critical patent/FR11C0002I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Seasonings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/AU95/00086 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Feb. 23, 1995 PCT Pub. No. WO95/22993 PCT Pub. Date Aug. 31, 1995A method as described for testing the susceptibility of a person to asthma. The person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The substance is in the form of a dispersible dry powder containing an effective proportion of particles of a respirable size. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The same technique of dry powder inhalation can be used to test for the susceptibility of a person to rhinitus, to induce sputum and promote mucociliary clearance.
FR11C0002C 1994-02-25 2011-01-21 POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT Active FR11C0002I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM4114A AUPM411494A0 (en) 1994-02-25 1994-02-25 Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
PCT/AU1995/000086 WO1995022993A1 (en) 1994-02-25 1995-02-23 Method and device for the provocation of air passage narrowing and/or the induction of sputum

Publications (2)

Publication Number Publication Date
FR11C0002I1 FR11C0002I1 (en) 2011-01-25
FR11C0002I2 true FR11C0002I2 (en) 2016-03-25

Family

ID=3778730

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0002C Active FR11C0002I2 (en) 1994-02-25 2011-01-21 POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT

Country Status (15)

Country Link
US (1) US5817028A (en)
EP (1) EP0748228B8 (en)
JP (7) JP3979660B2 (en)
KR (1) KR100385675B1 (en)
CN (1) CN1075737C (en)
AT (1) ATE474583T1 (en)
AU (2) AUPM411494A0 (en)
CA (1) CA2183471C (en)
DE (2) DE122011000004I1 (en)
DK (1) DK0748228T3 (en)
ES (1) ES2349027T3 (en)
FR (1) FR11C0002I2 (en)
NZ (1) NZ281522A (en)
PT (1) PT748228E (en)
WO (1) WO1995022993A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
NZ332313A (en) 1996-04-16 2000-02-28 Bayer Ag D-mannitol and its preparation as a powder of not more than 1 square meter per gram
US6235947B1 (en) * 1997-04-14 2001-05-22 Takeda Chemical Industries, Ltd. D-mannitol and its preparation
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US7027869B2 (en) 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US6634363B1 (en) 1997-04-07 2003-10-21 Broncus Technologies, Inc. Methods of treating lungs having reversible obstructive pulmonary disease
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
US7198635B2 (en) 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US8181656B2 (en) * 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
KR20010099865A (en) 1998-12-22 2001-11-09 프란시스 제이 메이어 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
PT1169065E (en) 1999-04-21 2005-07-29 1357784 Ontario Inc FORMULATIONS FOR ASTHMA DETECTION
AU2001241636A1 (en) * 2000-02-23 2001-09-03 The Procter And Gamble Company Halotherapy method
US8251070B2 (en) * 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
GB0014898D0 (en) * 2000-06-19 2000-08-09 Innovata Biomed Ltd Delivery system
US7104987B2 (en) 2000-10-17 2006-09-12 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
EP1531795A4 (en) * 2002-05-02 2011-02-23 Harvard College FORMULATIONS LIMITING THE EXTENSION OF PULMONARY INFECTIONS
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070053844A1 (en) * 2005-05-18 2007-03-08 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
JP2010502739A (en) * 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド Improvement of mucosal hydration and mucus clearance by treatment with sodium channel inhibitors and osmotic regulators
CA2663041A1 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US8714153B2 (en) * 2007-04-16 2014-05-06 Ric Investments, Llc Method for selecting a device adapted to treat disordered breathing
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
BRPI0907823A2 (en) 2008-02-26 2015-07-21 Parion Sciences Inc Polyaromatic Sodium Channel Blockers
CN102014779B (en) 2008-05-09 2014-10-22 赫莱拉公司 Systems, assemblies and methods for treating the bronchial tree
ES2625260T5 (en) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Dry powder formulations and methods for the treatment of lung diseases
CA2779135C (en) 2009-10-27 2018-09-04 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
MD4039C1 (en) * 2009-11-05 2010-12-31 Институт Химии Академии Наук Молдовы Surface artificial microsalt mine
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CA2780608C (en) 2009-11-11 2019-02-26 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
MD4089C1 (en) * 2009-11-18 2011-08-31 Институт Химии Академии Наук Молдовы Artificial surface halochamber
MD4040C1 (en) * 2009-12-09 2010-12-31 Институт Химии Академии Наук Молдовы Surface artificial halochamber
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CN103732213A (en) 2011-06-07 2014-04-16 帕里昂科学公司 Methods of treatment
AR086745A1 (en) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE
CA2839709C (en) 2011-06-27 2020-01-14 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
EP2819672A1 (en) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
EP3366680B1 (en) 2012-05-29 2020-05-13 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
EP3868321B1 (en) 2012-06-04 2022-11-16 Boston Scientific Scimed, Inc. Systems for treating tissue of a passageway within a body
US9592086B2 (en) 2012-07-24 2017-03-14 Boston Scientific Scimed, Inc. Electrodes for tissue treatment
US9272132B2 (en) 2012-11-02 2016-03-01 Boston Scientific Scimed, Inc. Medical device for treating airways and related methods of use
WO2014071372A1 (en) 2012-11-05 2014-05-08 Boston Scientific Scimed, Inc. Devices for delivering energy to body lumens
RU2015129065A (en) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. CHLORINE-PYRAZINCARBOXAMIDE DERIVATIVES THAT HAVE AN ACTIVATING BLOCKING OF EPITELIAL SODIUM CHANNELS
CN104995178B (en) 2012-12-17 2018-06-26 帕里昂科学公司 3,5-Diamino-6-chloro-N-(N-(4-phenylbutyl)formamidino)pyrazine-2-carboxamide
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
MX2015013845A (en) 2013-04-01 2016-05-09 Pulmatrix Inc Tiotropium dry powders.
CN105451680B (en) 2013-08-09 2019-10-08 波士顿科学国际有限公司 Expandable catheters and related methods of manufacture and use
CN104510726A (en) * 2013-09-27 2015-04-15 张金华 Dry salt powder inhalant for cleaning respiratory tract system
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
KR102288656B1 (en) 2020-12-02 2021-08-12 순천향대학교 산학협력단 PCR kit for diagnosis of asthma or exacerbation of asthma and method of providing information for diagnosis of asthma or exacerbation of asthma using the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623936A (en) * 1979-08-01 1981-03-06 Chest Corp Measuring apparatus of trachea hypersensitivity
NL8020393A (en) * 1979-10-30 1981-09-01 Riker Laboratories, Inc. Te Loughborough, Groot-Brittannie.
EP0041783B1 (en) * 1980-06-06 1984-12-05 FISONS plc Inhalation device for powdered medicaments
ES506585A0 (en) * 1980-10-30 1982-09-01 Riker Laboratories Inc A DEVICE TO FACILITATE THE ORAL INHALATION OF MEDICINES IN THE FORM OF POWDER
JPS6168418A (en) * 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd Expectorant
DE3518665C2 (en) * 1985-05-23 1994-03-17 Hoelter Heinz Wood filter for generating cleaned and naturally fragrant breathing air
IT1204826B (en) * 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
CA1317194C (en) * 1989-05-31 1993-05-04 Yves Cloutier Device for specific inhalation challenge, method of use and improved generator of particules
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
NL9002706A (en) * 1990-12-10 1992-07-01 Pharmachemie Bv Apparatus for use when inhaling powdered materials packaged in rod capsules.
GB9101592D0 (en) * 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
AU2746292A (en) * 1991-10-30 1993-05-06 Kenneth Roy Hanson Asthma and other allergies cure
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
SE9203743D0 (en) * 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5558085A (en) * 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
DE69431290D1 (en) * 1993-02-12 2002-10-10 Avant Immunotherapeutics Inc PULMONARY ADMINISTRATION OF THE TYPE 1 SCR1 SOLUBLE COMPLEMENT RECEPTOR
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9408053D0 (en) * 1994-04-22 1994-06-15 Nat Heart & Lung Inst Pharmaceutical preparation
US5509404A (en) * 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery

Also Published As

Publication number Publication date
JP2011148839A (en) 2011-08-04
NZ281522A (en) 1998-09-24
DE122011000004I1 (en) 2011-05-05
AUPM411494A0 (en) 1994-03-24
CN1075737C (en) 2001-12-05
JPH10501790A (en) 1998-02-17
JP2013136564A (en) 2013-07-11
JP2007056040A (en) 2007-03-08
JP3979660B2 (en) 2007-09-19
EP0748228A1 (en) 1996-12-18
JP2013049708A (en) 2013-03-14
ES2349027T3 (en) 2010-12-21
US5817028A (en) 1998-10-06
EP0748228B1 (en) 2010-07-21
EP0748228A4 (en) 1999-12-22
JP2011148840A (en) 2011-08-04
DK0748228T3 (en) 2010-10-11
DE69536090D1 (en) 2010-09-02
EP0748228B8 (en) 2010-08-25
KR100385675B1 (en) 2003-10-10
AU1748295A (en) 1995-09-11
FR11C0002I1 (en) 2011-01-25
JP2007056039A (en) 2007-03-08
AU682756B2 (en) 1997-10-16
CA2183471A1 (en) 1995-08-31
CA2183471C (en) 2008-07-29
CN1142190A (en) 1997-02-05
WO1995022993A1 (en) 1995-08-31
ATE474583T1 (en) 2010-08-15
PT748228E (en) 2010-09-15

Similar Documents

Publication Publication Date Title
FR11C0002I2 (en) POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT
Fubini et al. Chemical aspects of the toxicity of inhaled mineral dusts
Wei et al. Airborne spread of infectious agents in the indoor environment
Tsuda et al. Particle transport and deposition: basic physics of particle kinetics
Swift et al. Inspiratory deposition of ultrafine particles in human nasal replicate cast
Johnson et al. The mechanism of breath aerosol formation
TR199902556T2 (en) Halotherapy application method.
Brand et al. Aerosol bolus dispersion in healthy subjects
Adamis et al. In vitro and in vivo tests for determination of the pathogenicity of quartz, diatomaceous earth, mordenite and clinoptilolite
SCHEUCH et al. An approach to deposition and clearance measurements in human airways
Sturm Deposition and cellular interaction of cancer‐inducing particles in the human respiratory tract: Theoretical approaches and experimental data
Duan et al. Measuring the administered dose of particles on the facial mucosa of a realistic human model
Georges et al. Circadian variation in exhaled nitric oxide in nocturnal asthma
Finlay et al. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types
Chan et al. Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract
Antonini et al. Effect of short‐term exogenous pulmonary surfactant treatment on acute lung damage associated with the intratracheal instillation of silica
Korpi et al. Slight respiratory irritation but not inflammation in mice exposed to (1→ 3)‐β‐D‐glucan aerosols
MY115838A (en) Method and device for the provocation of air passage narrowing and/or the induction of sputum
Häkkinen et al. The effect of breathing frequency on deposition of drug aerosol using an inhalation‐synchronized dosimeter in healthy adults
Polatli et al. Perlite exposure and 4-year change in lung function
Richter et al. Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction
Sankhala et al. Factors that affect the lung deposition
Schlesinger et al. Pulmonary effects of repeated episodic exposures to nitric acid vapor alone and in combination with ozone
Solomon et al. Detection of inflammation and oxidative lung injury in exhaled breath condensate of rats with acute lung injury due to Staphylococcal enterotoxin B
Hesbert et al. Interdependence of polymorphonuclear neutrophils and macrophages stained for N-acetyl-β-glucos-aminidase in lavage effluents from toluene diisocyanate-exposed rat lungs